Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

12 Customer Reviews

  • PDGF-AA induces Ezh2 expression and proliferation in juvenile islets but not in adult islets. Western immunoblots of indicated islet proteins from 3 week or 9 month-old WT islets 2 days after exposure to PDGF-AA alone, or PDGF-AA plus RTK inhibitors Sunitinib.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

    Assessment of effects on human juvenile or adult islets after exposure to PDGF-AA (50 ng/ml) for 2 days, with or without Sunitinib (2 uM) or U0126 (10 uM)co-treatment. Average percentage of BrdU+ insulin+ cells was morphometry from sectioned islets immunostained for insulin (green), glucagon (white) and BrdU (red). n = 3-6 independent experiments.

    Nature 2011 478(7369):349-55. Sunitinib Malate purchased from Selleck.

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Sunitinib Malate purchased from Selleck.

    A, Tumor growth curves from the initial sunitinib drug trials, with endpoint set at 1,300 mm3 (mean ± SEM). Measurements began one week after tumor inoculation and on the day sunitinib treatment began. Subsequent experimental endpoints were set on the basis of these growth curves and their intersections with this data are shown. B, Histogram plot showing the distribution of tumor sizes at day 8 of treatment. Sunitinib-treated tumors exceeding 250 mm3 in size were identified as falling into the nonresponsive cohort. Sunitinib treatment significantly retards growth of responsive tumors.

    Cancer Res, 2017, 77(4):1008-1020 . Sunitinib Malate purchased from Selleck.

  • Sunitinib decreases FLT-3 and RET phosphor ylation but increases ERK phosphorylation in a time-dependent manner. H295R and SW13 cells were treated with sunitinib (10 nM) for various time points as indi-cated. Cell lysates were prepared and phospho-FLT-3, RET, and ERK levels were monitored by Western Blot-ting. Re-probing against FLT-3, RET, and ERK was done to ensure equal protein loading.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

    Sunitinib or PD98059 decreases cell proliferation in a dose-dependent manner. H295R and SW13 cells were treated with various concentration of sunitinib or PD98059 for 48 hours as indicated. Treated cells were subjected to the MTS proliferation assay. Similar experiments were repeated 3 times. Histograms represent relative % of OD490 nm absorbance (* P < .05). All data are relative multiples of expression compared with untreated cells. The data are representative of three experiments and are expressed as the mean ?SE.

    Surgery 2012 152, 1045-50. Sunitinib Malate purchased from Selleck.

  • Autophagic activation in sunitinib- and sorafenib- but not AZD6244-treated cells. Medullary thyroid cancer-1.1 (MTC-1.1; A) and TT ( B) cells were treated with dimethyl sulfoxide (DMSO), sunitinib (50 nM), sorafenib (10 nM), AZD6244 (30 nM), or everolimus (20 nM) for 48 hours. Cell lysates were prepared, and light chain 3 (LC3)-I and -II cleaved caspase-3 protein levels were monitored by Western blotting. Reprobing against actin was per formed to ensure equal protein loading. ( C ) MTC-1.1 and TT cells were transiently transfected with autophagy protein 5 (Atg-5) small inter fering RNA. Transfection with scrambled small inter fering RNA was used as a control. After transfection, cells with and without Atg-5 knockdown were exposed to DMSO or 20 nM of everolimus for 48 hours. Cell lysates were pre- pared and LC3-I and -II protein expression levels were monitored by Western blotting. Reprobing against Atg-5 was per formed to monitor Atg-5 knockdown efficiency. Reprobing against actin was per formed to ensure equal protein.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

    Autophagy inhibition blocks the antiproliferative effects of sunitinib and sorafenib but not AZD6244. Medullary thyroid cancer–1.1 (MTC-1.1) and TT cells were transfected transiently with scrambled or autophagy protein 5 (Atg-5) small inter fering RNA. After transfection, cells with and without Atg-5 knockdown were exposed to sunitinib (50 nM), sorafenib (10 nM), and AZD6244 (30 nM) for 48 hours. Treated cells were subjected to a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium proliferation assay. Similar experiments were repeated 3 times. Histograms represent the relative percent of OD490 nM absorbance. The asterisk indicates significance versus scrambled small inter fering RNA–treated control ( P < .05). All data are relative multiples of expression compared to untreated cells. The data are representative of 3 experiments and are expressed as the mean ± the standard error.

    Surgery 2012 152, 1142-9. Sunitinib Malate purchased from Selleck.

  • Sunitinib limits the colonial growth of HT-29 by downregulating HIF-1a. (A) The number and size of colonies formed in soft agar. The numbers of small colonies (<50 μm diameter) were not different among conditions of a serial concentration of sunitinib. On the contrary, large colonies (>50 μm diameter) disappeared after incubation with sunitinib. Each point represents the mean and SD from four separate experiments. (B) HIF-1a expression and hypoxia within HT-29 colony. After colonies grew for 4 weeks, HIF-1a and hypoxia were visualized by immunofluoroscence staining. Bar = 20 μm.

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    2. Sunitinib downregulates HIF-1a. (A) Dose-dependent repression of HIF-1a protein level by sunitinib in HT-29. HT-29 cells were incubated under normoxic (N) or hypoxic (H) conditions in the presence of sunitinib for 24 h. HIF-1a and ARNT proteins in total cell lysates were analyzed by Western blotting. (B) Sunitinib attenuates the hypoxic induction of HIF-1 target genes. RNAs were isolated from HT-29 cells subjected to normoxia (N) or hypoxia (H) in the presence of sunitinib for 16 h. The mRNAs of HIF-1a and its target genes were analyzed by RT-PCR and autoradiography. PGK1 indicates phosphoglycerate kinase 1; PDK1, pyruvate dyhydrogenase kinase 1; CAIX, carbonic anhydrase IX. (C) Sunitinib-induced HIF-1 inhibition. Epo-enhancer and b- galactosidase reporter plasmids were co-transfected into HEK293 cells. After 16 h incubation, luciferase and b-galactosidase activities were measured. *P < .05 versus the hypoxic control.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

  • Sunitinib inhibits 50-UTR-dependent translation of HIF-1a. (A) 50 cap-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the tk promoter and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 lg per 100-mm dish) and the b-gal plasmid (4 μg). After 16 h incubation under normoxic or hypoxic conditions with sunitinib, cells were lysed and subjected to luciferase assay. *P < .05 versus the hypoxic control. (B) IRES-dependent translational activity of HIF-1a. The luciferase reporter plasmid contains the HIF-1a 50-UTR segment between the GFP gene and the luciferase gene. HT-29 cells were co-transfected with the reporter plasmid (8 μg) and the b-gal plasmid (4 μg). *P < .05 versus the hypoxic control. (C) Sunitinib inhibits phosphorylation of Akt. After 8 h incubation under hypoxic condition with sunitinib, HT-29 cells were lysed and subjected to Western blotting. (D) Sunitinib suppresses HIF-1a in VHL-null RCC4 cells. VHL (-/-) RCC4 cells were incubated under normoxic conditions sunitinib for 8 h, and HIF-1a in total cell lysates was analyzed by Western blotting.

     

     

    Biochem Bioph Res Co 2010 398, 205–211. Sunitinib Malate purchased from Selleck.

    Experimental layout for VEGF signaling blocking and LCMV infection in WT mice. Mice received two injections on day 0 and 3 p.i. of Abs as described in Material and Methods, or daily gavage of the VEGFR/PDGFR-inhibitor sunitinib. Inguinal LN volume on day 0 (D0) or day 8 (D8) p.i. after treatment of mice with control Ig or anti-VEGFR2, anti-VEGF-A Abs or sunitinib. Pooled from 1-2 independent experiments with 3-5 mice per treatment. D. Total HEV length on day 0 (D0) or day 8 (D8) p.i. as in C. No significant difference was found in C and D between day 8 control Ig and Ab- or inhibitor-treated values (One-way ANOVA).

    AACR Sunitinib Malate purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 NIL0SVhMcW6jc3WgRZN{[Xl? NX7jTVZbUW6qaXLpeIlwdiCxZjDQSGdHNWmwZIXj[YQhSnKmVTDpcoNwenCxcnH0bY9vKHerdHigTWM2OCCxZjCwMlAxPyEQvF2= NYT6T4NqOTJ4NE[wNVk>
3T3 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\BfVZKdmirYnn0bY9vKG:oIGDsZZRmdGW2LXTldol3\WRiZ4Lve5RpKG[jY4TvdkBqdmS3Y3XkJFNVOyClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODFizszN M1jmNlEzPjR4MEG5
3T3 MUnGeY5kfGmxbjDBd5NigQ>? MoP0TY5pcWKrdHnvckBw\iCYYYPjeYxieiCnbnTveIhmdGmjbDDndo94fGhiZnHjeI9zKHKnY3XweI9zKHerdHigTWM2OCCxZjCwMlA2KM7:TR?= Mm\FNVI3PDZyMUm=
3T3 MofuT4lv[XOnIFHzd4F6 MoDHNlAhdWmw MlzGSG1UVw>? NVfJWJNbS2WubIXsZZIhcW6qaXLpeIlwdiCxZjDWSWdHKGmwZIXj[YQhcHWvYX6gT2RTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNlIh|ryP MV6xOlE3OjByOB?=
NIH3T3 NYjLbJJHU2mwYYPlJGF{e2G7 NWHTO25{OjBibXnu Mn\mSG1UVw>? NEDwdnRqdmirYnn0JIh2dWGwIFvEVkBscW6jc3Wg[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkCxPEDPxE1? MlqwNVYyPjJyMEi=
A549 MVHGeY5kfGmxbjDBd5NigQ>? MmLhSG1UVw>? NV;nbIgxUW6qaXLpeIlwdiCxZjDjMW1mfCCmZYDlcoRmdnRiSFfGMYlv\HWlZXSgbJVu[W5iQUW0PUBk\WyuIH3p[5JifGmxbjD3bZRpKEmFNUCgc4YhOiEQvF2= MlzjNVg1OzRzNEW=
DU145 M2S5VmZ2dmO2aX;uJGF{e2G7 M17IRmROW09? MmXGTY5pcWKrdHnvckBw\iClLV3leEBl\XCnbnTlcpQhUEeILXnu[JVk\WRiaIXtZY4hTFVzNEWgZ4VtdCC|Y3H0eIVzcW6pIIfpeIghUUN3MDDv[kAyOCEQvF2= NEXhW4UyQDR|NEG0OS=>
KB3-1 NITYWZJEgXSxdH;4bYMhSXO|YYm= MUm3NkBp NInHfGpFVVOR Ml;NR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVE1oeC2wZXfheIl3\SCNQj2zMVEh[2WubIOge4l1cCCLQ{WwJI9nKDJwMzFOwG0> MXSxPVM6PzN{Mh?=
KBV1 NVXrSnhKS3m2b4TvfIlkKEG|c3H5 NEnTN3U4OiCq MYXEUXNQ MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdtgWOxcILveIVqdi2neIDy[ZN{cW6pIFvCWlEh[2WubIOge4l1cCCLQ{WwJI9nKDRwMTFOwG0> NGToZ5YyQTN7N{OyNi=>
A375 NUPrVI5MS3m2b4TvfIlkKEG|c3H5 NVfVTGhHPzJiaB?= M3TQfmROW09? MWjJR|UxRTVwNDFOwG0> M4Kxd|E6PjV2NEC4
RS4-11 NHXBbW1HfW6ldHnvckBCe3OjeR?= NYTJV5BtOiCq MXTJcohq[mm2aX;uJI9nKE[OVEOgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFk6KM7:TR?= NXfOcpo1OTl4NUS0NFg>
RS4-11 NYm4ZlVITnWwY4Tpc44hSXO|YYm= Ml22NkBp NInoZYJKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjB|NDFOwG0> MmDzNVk3PTR2MEi=
Sf9 NYnHeIpJU2mwYYPlJGF{e2G7 M{XYe|MxKG2rbh?= NGLwTWhKdmirYnn0bY9vKG:oIFfTWE11[WepZXSgWmVITlJiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjF6NTFOwG0> M4HJbVE6QDV2MEWx
Ba/F3 M{PoRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnQXII4OiCq NFi2b21KSzVyPUGuNkDPxE1? NVv4bFdFOjBzMUewNFQ>
BaPTC2 NFTQeYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVW3NkBp Mkj5TWM2OD1yLkKyJO69VQ>? M1njUVIxOTF5MEC0
Sf9 MkXSSpVv[3Srb36gRZN{[Xl? NXfpPXFlOSCq NVnVeWVHTE2VTx?= M{WwbmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSHnzMZRi\2enZDDSSXQh\XiycnXzd4VlKHerdHigTWM2OCCxZjCxMlMh|ryP MlO1NlAyOTdyMES=
H4 NEXqZZlEgXSxdH;4bYMhSXO|YYm= M{PERVExKM7:TR?= NILwdFNVd3irY3n0fUBqdiCqdX3hckBJPCClZXzsdy=> M4XmPVIxOzVyOEC2
SF-539 MonUT4lv[XOnIFHzd4F6 MWSzN|Mh|ryP NYLVXJd2PjBibXnu M1XSNGROW09? MliwTY5pcWKrdHnvckBw\iCSRFfGVoJmfGFicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxNk4zKM7:TR?= MlXMNlA1ODN5MEC=
U251 M2nzT2tqdmG|ZTDBd5NigQ>? NWjRWFhCOzN|IN88US=> NVe4e2NLPjBibXnu M{C1XGROW09? NUTyWod3UW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxPE46KM7:TR?= MXKyNFQxOzdyMB?=
A431 M2mxbmtqdmG|ZTDBd5NigQ>? MmTpTY5pcWKrdHnvckBw\iCSRFfGVoJmfGFiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyOi5{IN88US=> NGHjfpUzODV3OEC3Ni=>
A431 M3jsNmtqdmG|ZTDBd5NigQ>? M2jNeGlvcGmkaYTpc44hd2ZiVlXHSnIzKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNVgvQSEQvF2= M1\EPVIxPTV6MEey
HepG2 NFTqToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUO3NkBp M1K4T2lEPTB;Mz64NUDPxE1? MV[yNFU4ODV{Nh?=
Kasumi-1 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW3NkBp NFPhWplKSzVyPUCuNFE3KM7:TR?= MUmyNFU4ODV{Nh?=
RS4-11 MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;QZ2c3PzJiaB?= MY\JR|UxRTFizszN NXvOTIQ2OjB3N{C1NlY>
THP1 NIThN|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW3NkBp MULJR|UxRTBwNTFOwG0> MVKyNFU4ODV{Nh?=
Kasumi-1 NEHzemFHfW6ldHnvckBCe3OjeR?= MWjJcohq[mm2aX;uJI9nKGNvS3n0JIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFE2KM7:TR?= MX2yNFg{OzB|OR?=
A549 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjQVmV3OTZiaB?= MnzwRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\Wyucx?= NWWwWnhsOjF2NUC0OlM>
HL60 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnzNVYhcA>? NXywVFNJSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTGw3OCClZXzsdy=> NWnLUG1kOjF2NUC0OlM>
HUVEC MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D6bFE3KGh? NIXzN4dKdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIEKuO|Uh|ryP NWTaU4tIOjF2NUC0OlM>
HUVEC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LFc|E3KGh? NVW0cHQ6UW6qaXLpeIlwdiCxZjDiSmdHNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjC0MlA1KM7:TR?= MUeyNVQ2ODR4Mx?=
IM9 M2DuZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm0T5hTOTZiaB?= MmTzRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSV25JINmdGy| MYeyNVQ2ODR4Mx?=
K562 M4noOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLvdYlGOTZiaB?= MUfBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy| MUOyNVQ2ODR4Mx?=
MDA-MB-231 NI\GW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSxOkBp M4jtXWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHN? M1L0WFIyPDVyNE[z
H460 MYHDfZRwfG:6aXOgRZN{[Xl? M4LWNVczKGh? NEnCOnRKSzVyPUKuO{DPxE1? NFLycIozOTZ{MUi4NC=>
SMMC7721 NFzhRnJEgXSxdH;4bYMhSXO|YYm= MkXlO|IhcA>? NVzTd3gyUUN3ME22MlQ4KM7:TR?= MkPBNlE3OjF6OEC=
WI38 MY\DfZRwfG:6aXOgRZN{[Xl? NX3YT3FHPzJiaB?= MVfJR|UxRThwNU[g{txO M4e3VVIyPjJzOEiw
HEK293 MUHLbY5ie2ViQYPzZZk> MnXXNVAxKG6P NEDrT20yKGh? MXTkc4V{KG6xdDDpcohq[mm2IG\FS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKG:oIIT5do9{cW6nIEGxO|UhemW|aXT1[UBwdiCYRVfGVlIh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsdy=> MVmyNVg5PTJ6Nx?=
HUVEC M2DDWWZ2dmO2aX;uJGF{e2G7 Mln4NUDPxE1? MoPyNlQhcA>? MYLBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBXTUeILXnu[JVk\WRiY3XscEBucWe{YYTpc44> NH\SNVgzOTl4M{OwOS=>
HUVEC M1;RUmZ2dmO2aX;uJGF{e2G7 MUixJO69VQ>? MmfVNUBp MkC0TY5pcWKrdHnvckBw\iCHUlugdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejJyMj;UfZIzODRiaX6gWmVITi2|dHnteYxifGWmIFjVWmVE NHnJfmYzOTl4M{OwOS=>
HUVEC MX;GeY5kfGmxbjDBd5NigQ>? M2Xze|Eh|ryP NGr3WHAyKGh? MYDJcohq[mm2aX;uJI9nKGWQT2OgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmei1zMUeyJIlvKF[HR1[td5RqdXWuYYTl[EBJXV[HQx?= NVTG[3pZOjF7NkOzNFU>
HUVEC M1zoVGtqdmG|ZTDBd5NigQ>? M1rWXVEh|ryP NGHRcFAyKGh? NHfMOYlKdmirYnn0bY9vKG:oIG\FS2ZTOiCyaH;zdIhwenmuYYTpc44h[XRidInyMVEyPzViaX6gWmVITi2|dHnteYxifGWmIFjVWmVE NG\qbpkzOTl4M{OwOS=>
HUVEC MXrGeY5kfGmxbjDBd5NigQ>? NFfDUncyKM7:TR?= MYWxJIg> M3P3T4Rw\XNibn;0JIlvcGmkaYSgRWtVKHCqb4PwbI9zgWyjdHnvckBifCCVZYKtOFc{KGmwIG\FS2Yue3SrbYXsZZRm\CCKVW\FRy=> MVeyNVk3OzNyNR?=
HL60 MlXMR5l1d3SxeHnjJGF{e2G7 NHjC[ok2OCEQvF2= NUjRb5A6PDhiaB?= M3ztNmROW09? Ml3GTWM2OD1zNT61JO69VQ>? MWCyNlAyQTF6OB?=
K562 NYH4cGt5S3m2b4TvfIlkKEG|c3H5 MkC5OVAh|ryP NYnleZhSPDhiaB?= M3v2TGROW09? M37jcGlEPTB;MkGuPUDPxE1? MUiyNlAyQTF6OB?=
PC3 NXPOcWhwS3m2b4TvfIlkKEG|c3H5 M{D1ZVUxKM7:TR?= M{K0PFQ5KGh? M4C2eGROW09? MUjJR|UxRTJ3LkGg{txO M2OyUVIzODF7MUi4
SF-539 M1\3W2tqdmG|ZTDBd5NigQ>? MXezN|Mh|ryP NHzycWM3OCCvaX6= MV3Jcohq[mm2aX;uJI9nKFCGR1\SZoV1[SC2eYLvd4lv\SCtaX7hd4Uh[WO2aY\peJkhcW5iUFTHSk1DSi2|dHnteYxifGWmIHj1cYFvKFOILUWzPUBk\WyuczD3bZRpKEmFNUCgc4YhOTJwMjFOwG0> MXiyNlIxPDd2MR?=
HAEC NIjQVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vGb|ExOCEQvF2= MYm3NkBp MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiDRVOgZ4VtdHNiZYjwdoV{e2mwZzDWSWdHWiC5aYToJGlEPTBib3[gNE4yKM7:TR?= NHvRV|QzOjR2NE[3PS=>
HT-29 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXDSXkyODBizszN MnTEO|IhcA>? NIXVSmJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIV5eHKnc4PpcochXkWJRmKge4l1cCCLQ{WwJI9nKDBwM{Og{txO NHfVVZQzOjR2NE[3PS=>
MV4-11 MUHDfZRwfG:6aXOgRZN{[Xl? MU[3NkBp NEDRbHlKSzVyPUCuNFA{KM7:TR?= MknBNlI1PTJ3MUi=
HepG2 NHXxcopEgXSxdH;4bYMhSXO|YYm= M{DRSVQ5KGh? MXjJR|UxRTF|LkK0JO69VQ>? NGXGUZkzOjR6M{[wPC=>
PC9 M4DMfGN6fG:2b4jpZ{BCe3OjeR?= NEfZVFg1QCCq NV:2UYFPUUN3ME2xNE46PyEQvF2= NFrCfpQzOjR6M{[wPC=>
CAKI-1 NVLTV48yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\3Z3gyODBizszN NGPZepA1QCCq M4PrU2ROW09? NUK2UHh5T0l3ME2wMlY{KM7:TR?= M3q4dlIzPTZyNkK3
EKVX MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX2XpQyODBizszN MlvUOFghcA>? NEj1OGFFVVOR MlvTS2k2OD15Lkmg{txO NYHQRpI4OjJ3NkC2Nlc>
MCF7 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjUSWQyODBizszN MVO0PEBp MYDEUXNQ NXTlTWY5T0l3MU2yJO69VQ>? MnjPNlI2PjB4Mke=
MDA-MB-435 NF;ydVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULodld2OTByIN88US=> MoDkOFghcA>? Mn;oSG1UVw>? MYjHTVUzRTJizszN M{np[lIzPTZyNkK3
OVCAR3 NVLJeIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDPNVAxKM7:TR?= Ml\pOFghcA>? MUnEUXNQ NXf6OJRkT0l3M{2zMlIh|ryP MnXRNlI2PjB4Mke=
SNB19 NH;YcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzENVAxKM7:TR?= Mnr5OFghcA>? M2fyOWROW09? MYrHTVU1RTFyIN88US=> MXWyNlU3ODZ{Nx?=
SW620 NWfOOZlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVixNFAh|ryP MV[0PEBp MXzEUXNQ M{fZfWdKPTV;MT6zJO69VQ>? NHL5TGozOjV4ME[yOy=>
TK10 NH\IU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnvOYxHOTByIN88US=> M4TtRlQ5KGh? M3zIWmROW09? M{nrN2dKPTZ;Nj6zJO69VQ>? NGD2bmIzOjV4ME[yOy=>
UACC257 M2TBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iwNlExOCEQvF2= MYG0PEBp Mn76SG1UVw>? NXLIUGc6T0l3N{20JO69VQ>? MX2yNlU3ODZ{Nx?=
HAEC M2nrWWN6fG:2b4jpZ{BCe3OjeR?= MkXYNVAxKM7:TR?= MWO3NkBp Mmf0SG1UVw>? MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBXTUeIUjDlfJBz\XO|aX7nJGhCTUNid3n0bEBKSzVyIH;mJFAvOSEQvF2= NIW5WVgzOzF|MUW0NS=>
HT-29 Mlj4R5l1d3SxeHnjJGF{e2G7 MnLTNVAxKM7:TR?= MXq3NkBp NX[4R2xwTE2VTx?= Mn3YR5l1d3SxeHnjbZR6KGGpYXnud5QhXkWJRmKg[ZhxemW|c3nu[{BpfW2jbjDIWE0zQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1? NIrZXmozOzF|MUW0NS=>
HCT116 M2\lS2Z2dmO2aX;uJGF{e2G7 MYKyOEBp MVTEUXNQ MV;BcpRqdWmpcnH0c5J6KGGldHn2bZR6KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDtbYdz[XSrb36= NH3OTWUzOzF3M{KwNC=>
HUVEC MkDvSpVv[3Srb36gRZN{[Xl? MXiyJO69VQ>? Mn35NVghcA>? MUXEUXNQ MWLBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGS3NidX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fWKnIH\vdo1ifGmxbh?= MoLKNlMyPTN{MEC=
ACHN MULDfZRwfG:6aXOgRZN{[Xl? NYDzfpJ[PiCm NFLDPYRKSzVyPUKuOUDPxE1? NWXLVHRzOjN|NkCxNFQ>
A498 Ml33R5l1d3SxeHnjJGF{e2G7 M4i0NVExOCEQvF2= MmHNO|IhcA>? NXHPdFNxTE2VTx?= NVzUd2pHUUN3ME20MlMh|ryP NVvVcZhTOjN2OEm2NlY>
HUVEC NYTZOVR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Xq[lMh|ryP MVKyOEBp M121RmROW09? MYTBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKF[HR1[tbY5lfWOnZDD0eYJmKG[xcn3heIlwdiC5aYToJGVEPTBib3[gNE43PDVizszN MlW3NlM2QDN7MUG=
HUVEC MlzvT4lv[XOnIFHzd4F6 M2HRTVIxOCEQvF2= NV\SNWp4TE2VTx?= Ml7GTY5pcWKrdHnvckBw\iCYRVfGVlIheGixc4Doc5J6dGG2aX;uJIlvKGe{b4f0bEBn[WO2b4Ktd5RqdXWuYYTl[EBJXV[HQx?= M1y0TVI{PTh|OUGx
HUVEC MYTLbY5ie2ViQYPzZZk> MnrLNlAxKM7:TR?= NFW2e5NFVVOR NVv0NI0yUW6qaXLpeIlwdiCxZjDWSWdHWjFicHjvd5Bpd3K7bHH0bY9vKGmwIHfyc5d1cCCoYXP0c5Iue3SrbYXsZZRm\CCKVW\FRy=> MkfPNlM2QDN7MUG=
A549 MXnDfZRwfG:6aXOgRZN{[Xl? NVXxO|hXPzJiaB?= NInVO2NFVVOR MUfJR|UxRTJwNESg{txO NFnMZ4gzOzZyMkS0NS=>
HCT116 M4n3T2N6fG:2b4jpZ{BCe3OjeR?= MUi3NkBp NILmNWZFVVOR MUTJR|UxRTRwN{Gg{txO MWKyN|YxOjR2MR?=
MCF7 MWnDfZRwfG:6aXOgRZN{[Xl? Mnj0O|IhcA>? NWnOWZZJTE2VTx?= MkL2TWM2OD14LkK5JO69VQ>? MUWyN|YxOjR2MR?=
BGC NGfxWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr6O|IhcA>? MojQSG1UVw>? MV7JR|UxRTRwN{ig{txO M{\2[VI{QTl7MESw
BxPC3 M3\CW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXjO|IhcA>? NV[5NpVSTE2VTx?= NXLEfXZjUUN3ME2zMlY{KM7:TR?= MnH4NlM6QTlyNEC=
HT-29 M3LZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfkcY44OiCq MUPEUXNQ MVLJR|UxRTFwNEeg{txO NFrnUmgzOzl7OUC0NC=>
T24 M4nnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml65O|IhcA>? NE\tdYJFVVOR M{jFWmlEPTB;Mj60OEDPxE1? NFLIPFEzOzl7OUC0NC=>
4T1 MkG2R5l1d3SxeHnjJGF{e2G7 MXu3NkBp MWTEUXNQ NFXUV3FKSzVyPUCuNFE3KM7:TR?= M4j5V|I1QDlyNkWy
MCF7 NUTHXYN5S3m2b4TvfIlkKEG|c3H5 MWO3NkBp NHTO[FJFVVOR MonBTWM2OD1yLkCyO|Eh|ryP NG\pVWszPDh7ME[1Ni=>
MCF7 MWTDfZRwfG:6aXOgRZN{[Xl? MXi3NkBp MVHEUXNQ NESwRpBKSzVyPUCuNFI6OyEQvF2= NWHiNWZ5OjR6OUC2OVI>
MDA-MB-231 MnHhR5l1d3SxeHnjJGF{e2G7 NHztfGw4OiCq MnzTSG1UVw>? MlLkTWM2OD1yLkCyNlMh|ryP NXrVO2RmOjR6OUC2OVI>
MDA-MB-435 M{DSN2N6fG:2b4jpZ{BCe3OjeR?= NIfLWos4OiCq Mle1SG1UVw>? MX3JR|UxRTBwMEC5O{DPxE1? Moq0NlQ5QTB4NUK=
MDA-MB-468 NGf0PY5EgXSxdH;4bYMhSXO|YYm= MWG3NkBp NGPRfXlFVVOR NUOwVnR2UUN3ME2wMlAxPjFizszN NUPLTI13OjR6OUC2OVI>
A431 MnPJT4lv[XOnIFHzd4F6 M3zsVlExKM7:TR?= M3jmSFEhcA>? MmfRSG1UVw>? MoKyTY5pcWKrdHnvckBw\iCHR1\SJJdqfGhiSVO1NEBw\iByLkG3NlEh|ryP MXiyOFg6ODZ3Mh?=
SH-SY5Y Mm\NT4lv[XOnIFHzd4F6 M1u0b|ExKM7:TR?= M1nvZlEhcA>? MnLJSG1UVw>? M{Dyd2lvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIIfpeIghUUN3MDDv[kAxNjB6M{Gg{txO MlLnNlQ5QTB4NUK=
U251 NGqwOmNMcW6jc3WgRZN{[Xl? MWKxNEDPxE1? NV\aXItTOSCq MV;EUXNQ NETneIFKdmirYnn0bY9vKG:oIG\FS2ZTOiC5aYToJGlEPTBib3[gNE4xOTh7IN88US=> M2D6V|I1QDlyNkWy
Bel7402 M1HKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHVN4c4OiCq M12wOWROW09? M3zvcmlEPTB;Mj62O{DPxE1? MoDmNlQ6ODR7NkG=
HK2 NFH0SoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTIO|IhcA>? MXjEUXNQ NVPCdmJ4UUN3ME21Mlg2KM7:TR?= NXn2XZc2OjR7MES5OlE>
LO2 MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS2O|IhcA>? M2rITGROW09? MlHFTWM2OD1zOT65N{DPxE1? MYWyOFkxPDl4MR?=
MV4-11 NIPmS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrSWY1bPDhiaB?= M3XhOGROW09? NVfxTWhwUUN3ME2wMlAxOyEQvF2= M3PDSlI1QTB2OU[x
NCI-H3122 M2nNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T3R|czKGh? NHG3N21FVVOR M1Xwc2lEPTB;MD64N{DPxE1? MWCyOFkxPDl4MR?=
NCI-H460 MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPwXXpHPzJiaB?= M2HMXWROW09? M3LJeWlEPTB;ND6zNUDPxE1? M2PaXVI1QTB2OU[x
NCI-H526 NX3STmFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjiUWY2PzJiaB?= M2LRfGROW09? NX3xXHhMUUN3ME2xMlAyKM7:TR?= MXSyOFkxPDl4MR?=
TT MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;QXVczKGh? M3rWXWROW09? MWrJR|UxRTBwMESg{txO Ml3FNlQ6ODR7NkG=
EoL-1-cell M2TCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwNkSgdG0> MknVV2FPT0WU
MV-4-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\QNGlEPTB;MkeyJJBO NVuzd4xHW0GQR1XS
NOS-1 M1HjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzzVJFKSzVyPUG1MlMhdk1? NIC5V25USU6JRWK=
CGTH-W-1 NF7jSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNyLkm0JI5O MWDTRW5ITVJ?
MONO-MAC-6 NYTXR29bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTN|Lkigcm0> NU\neWNQW0GQR1XS
ALL-PO M4nO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTd7Lki5JI5O MnuzV2FPT0WU
NKM-1 M2i4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnqSphMUUN3ME25PE42OiCwTR?= M4G2VXNCVkeHUh?=
KM12 MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnHVFdvUUN3ME2zOVAvOTRibl2= MojIV2FPT0WU
TE-15 MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH3dWE3UUN3ME21NFcvPjFibl2= MYXTRW5ITVJ?
697 MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu4dHdKSzVyPU[xOE4zPSCwTR?= Ml7sV2FPT0WU
MOLT-16 NWjKU3NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O1O2lEPTB;NkOxMlMzKG6P NEjMZ4ZUSU6JRWK=
GB-1 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDnNGY6UUN3ME23NVAvOjNibl2= MnzyV2FPT0WU
TE-12 NETtcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfGdotMUUN3ME24NFQvPTVibl2= M{fqVHNCVkeHUh?=
ES6 NIj0bXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LBPGlEPTB;OUixMlA3KG6P M2T0WHNCVkeHUh?=
LC-2-ad Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C0VmlEPTB;MT6xNVQxPyEQvF2= MV;TRW5ITVJ?
BL-70 M1Hremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf0OmlKSzVyPUGuNVE5PDZizszN MnviV2FPT0WU
ETK-1 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\kXZdKSzVyPUGuNlg2QCEQvF2= MoP1V2FPT0WU
A4-Fuk MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7wTWM2OD1zLkO0NVQyKM7:TR?= NEO3bZFUSU6JRWK=
OCI-AML2 NEDzb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3uyRmlEPTB;MT6zOlg2OSEQvF2= NGPqOXpUSU6JRWK=
SIG-M5 M{LaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfOXZlKSzVyPUGuN|cxODlizszN MYfTRW5ITVJ?
NCI-SNU-16 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPkbI9KSzVyPUGuOFY1QDZizszN M3PqZXNCVkeHUh?=
PSN1 NFrGXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfvO2hKSzVyPUGuOVA3PzZizszN NG\Lc|JUSU6JRWK=
SR Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFwNUS1O|Ih|ryP MkTiV2FPT0WU
A3-KAW M{LwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHETWM2OD1zLk[yOVQ3KM7:TR?= MVzTRW5ITVJ?
KS-1 NIXBXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXBTWM2OD1zLk[5NlQ4KM7:TR?= M{nCeHNCVkeHUh?=
CTV-1 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFwN{K3OVEh|ryP MWnTRW5ITVJ?
LB1047-RCC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYWxbWNQUUN3ME2xMlgyPjJ2IN88US=> M{DiUXNCVkeHUh?=
EMG-01 NX\DW2EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HSS2lEPTB;MT64N|U3OyEQvF2= NELnRolUSU6JRWK=
TE-11 Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LKNmlEPTB;MT64N|k5PSEQvF2= NHLC[lVUSU6JRWK=
CMK NYC4[lhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYruUIxHUUN3ME2xMlk2PTF5IN88US=> MUjTRW5ITVJ?
NB1 Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3PW3h{UUN3ME2xMlk3OTF5IN88US=> MorCV2FPT0WU
HAL-01 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTJwMEW5OFYh|ryP M{PFPHNCVkeHUh?=
DEL M2nu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJwMEi0PFIh|ryP NU\zepRjW0GQR1XS
RL95-2 NGPr[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDYcYw3UUN3ME2yMlEyOTN5IN88US=> M1i5TXNCVkeHUh?=
KARPAS-299 M3nsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L6fmlEPTB;Mj6xNVMyOyEQvF2= NIr1W2FUSU6JRWK=
EW-16 NH7aVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFWwU3BKSzVyPUKuNVM2ODhizszN MleyV2FPT0WU
RS4-11 NHfnd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jjXWlEPTB;Mj6xO|kzPCEQvF2= MnLsV2FPT0WU
BB30-HNC NIHGN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm2R5pkUUN3ME2yMlIzOzd3IN88US=> NFGwTYJUSU6JRWK=
DOHH-2 M3n0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy5SXpKSzVyPUKuN|M1OzFizszN NVfBcnZ1W0GQR1XS
RPMI-8402 NHTjWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\xephbUUN3ME2yMlM{PjF6IN88US=> NWnLW2JJW0GQR1XS
BV-173 NXficIpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PhcWlEPTB;Mj6zN|Y3KM7:TR?= Ml;5V2FPT0WU
TE-10 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r1WmlEPTB;Mj6zOFM5PCEQvF2= NEj3NYNUSU6JRWK=
TE-8 NYK0WZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvEOHlKSzVyPUKuN|cxOzhizszN NVu4RmdMW0GQR1XS
K052 NX7VZ2dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHyTWM2OD1{LkSwNlAzKM7:TR?= NX23fIlzW0GQR1XS
KARPAS-45 MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJwNEm0OFYh|ryP NHzJ[plUSU6JRWK=
SK-NEP-1 NG[2dHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv1XXZHUUN3ME2yMlYxOjN5IN88US=> NX\KPHJWW0GQR1XS
KGN MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTYTWM2OD1{Lk[wN|M6KM7:TR?= NGrrUWxUSU6JRWK=
ML-2 MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\STWM2OD1{Lk[zOVEzKM7:TR?= Mn70V2FPT0WU
LAMA-84 M1y1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jGbmlEPTB;Mj62PVU1PSEQvF2= NIrLdHlUSU6JRWK=
LXF-289 NXrDU2NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KxSGlEPTB;Mj63Nlk5QSEQvF2= MYDTRW5ITVJ?
A101D NY\WXm5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n6W2lEPTB;Mj63PFMxPCEQvF2= M3ThTXNCVkeHUh?=
KY821 NHnzTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PSS2lEPTB;Mj63PVc2QCEQvF2= M3XYPXNCVkeHUh?=
ES4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvITWM2OD1{LkiwOlI5KM7:TR?= NF\kb2RUSU6JRWK=
SCC-3 NH7uUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnDUVRKSzVyPUKuPFI5QTFizszN MmfoV2FPT0WU
NALM-6 M1HmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwOUC0O|Mh|ryP Mn;JV2FPT0WU
BL-41 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LnOWlEPTB;Mj65NVIzOiEQvF2= MmTjV2FPT0WU
OPM-2 NX60RndoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTNwMEW5OVQh|ryP NUP6XG9GW0GQR1XS
SF126 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjETpR{UUN3ME2zMlA3OTl6IN88US=> NVm3O2xsW0GQR1XS
BE-13 MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nubWlEPTB;Mz6yN|EyOSEQvF2= NXS1cYx5W0GQR1XS
SF268 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTNwM{K4Olkh|ryP MmLwV2FPT0WU
MOLT-4 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LV[mlEPTB;Mz6zPVg{QCEQvF2= NVHHNFJDW0GQR1XS
PF-382 NF3t[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTNwNES1O{DPxE1? MojpV2FPT0WU
HEL NUDCOnNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml25TWM2OD1|LkS4NFA2KM7:TR?= NH2wWWpUSU6JRWK=
RPMI-6666 NF73NZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVGwc|Q2UUN3ME2zMlU1OTdzIN88US=> MW\TRW5ITVJ?
QIMR-WIL MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzrTWM2OD1|Lk[zN|kyKM7:TR?= M1qyN3NCVkeHUh?=
ATN-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzJeGtKSzVyPUOuOlcyOTRizszN MlTuV2FPT0WU
BB49-HNC NGjTUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvETWM2OD1|LkewOVA5KM7:TR?= NGSyV2tUSU6JRWK=
HCE-4 M2HDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\XTWM2OD1|Lke4OlQzKM7:TR?= NXz4VVBOW0GQR1XS
SK-LMS-1 NH;MT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXUTWM2OD1|LkizN|M5KM7:TR?= NHzW[I1USU6JRWK=
MS-1 NET6clZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPBXWNiUUN3ME2zMlg{Pzd6IN88US=> NWH3bGM3W0GQR1XS
JAR NEfmU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK3[JpKSzVyPUOuPVg5OzJizszN NVr5VXVqW0GQR1XS
KE-37 NIjlRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkezTWM2OD12LkC2NVU5KM7:TR?= M4PYNXNCVkeHUh?=
LB996-RCC M4XYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTRwMUKxOlgh|ryP NEHV[FRUSU6JRWK=
HH NHPme5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPYNZJKSzVyPUSuNlA6OTRizszN NYnPZ4NCW0GQR1XS
HL-60 NWHnNpA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37XUGlEPTB;ND6yNVA3PSEQvF2= NXj2bGM1W0GQR1XS
HOP-62 NF;RfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTRwM{O1NkDPxE1? Mmj3V2FPT0WU
NOMO-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjrTIN2UUN3ME20MlM{Pjl7IN88US=> NUPhNHlsW0GQR1XS
DU-4475 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M364bGlEPTB;ND6zOlczQSEQvF2= NID0PYdUSU6JRWK=
LC4-1 M2TD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH33NVFKSzVyPUSuN|gxPyEQvF2= NVXxcIhYW0GQR1XS
MC116 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHP[|JGUUN3ME20MlQ{ODhzIN88US=> NWjMe29yW0GQR1XS
SW982 NHnue4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPNTWM2OD12LkW1N|A4KM7:TR?= NWHORmFPW0GQR1XS
SK-N-DZ NVvpW4hET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnTTWM2OD12Lk[3NFk6KM7:TR?= M2\TZXNCVkeHUh?=
EW-1 NITudWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTRwNke5NVEh|ryP M1:wVHNCVkeHUh?=
SU-DHL-1 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDUfJFKSzVyPUSuPFAyPzRizszN MUnTRW5ITVJ?
L-363 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXVTWM2OD12LkiwOlIyKM7:TR?= NGPsVYpUSU6JRWK=
OS-RC-2 MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRwOEezNUDPxE1? NE\KT|RUSU6JRWK=
HD-MY-Z MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrPU4VKSzVyPUWuNVc{ODFizszN NFjuNWVUSU6JRWK=
MHH-PREB-1 NVHDTo5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;PNJJZUUN3ME21MlMzOzF{IN88US=> M2rxUXNCVkeHUh?=
HC-1 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTVwNEOyPVEh|ryP MoTBV2FPT0WU
SK-MM-2 NH;IWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHNTWM2OD13LkS3PFIh|ryP NYDjcmtKW0GQR1XS
SH-4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHizNmhKSzVyPUWuOFg{PyEQvF2= NH7yWVdUSU6JRWK=
MHH-CALL-2 MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;6SJY3UUN3ME21Mlc3PzF7IN88US=> Ml\1V2FPT0WU
KG-1 NYjVO3NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHSTWM2OD14LkCyPFc5KM7:TR?= M3TTN3NCVkeHUh?=
J-RT3-T3-5 NX\sTFFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3RNlVvUUN3ME22MlA4QTB7IN88US=> NHXIXnVUSU6JRWK=
MMAC-SF MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLqcJVnUUN3ME22MlExQTR7IN88US=> Ml3qV2FPT0WU
IST-SL2 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHyTWM2OD14LkGyOVE6KM7:TR?= NFvVXoFUSU6JRWK=
SW954 MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTZwMke1NVch|ryP MYnTRW5ITVJ?
HDLM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfJUHQxUUN3ME22MlMzOTB7IN88US=> MmjtV2FPT0WU
ST486 NESzUnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTZwM{S3NUDPxE1? M1LWfXNCVkeHUh?=
DG-75 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj3T|VKSzVyPU[uOFMxPjlizszN NHTVVlNUSU6JRWK=
EW-3 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3TU4RRUUN3ME22MlQ{OjB5IN88US=> Mnf4V2FPT0WU
8-MG-BA M1O5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGxTWM2OD14LkWxOVA4KM7:TR?= MkO2V2FPT0WU
GT3TKB M3jicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PLSGlEPTB;Nj62NFc3OyEQvF2= M4jRUnNCVkeHUh?=
KU812 NUfvTGlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDtTWM2OD14Lk[5OFIh|ryP M12zVHNCVkeHUh?=
CESS Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DlemlEPTB;Nz6xNFQ{QCEQvF2= NYjRcpdPW0GQR1XS
BC-1 M17uNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\CTW9{UUN3ME23MlI1QDF{IN88US=> MVPTRW5ITVJ?
MZ1-PC M{D2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fwV2lEPTB;Nz6zNFM5QSEQvF2= MnPuV2FPT0WU
NCI-H82 NUnqUnRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3iyS2lEPTB;Nz6zO|g2KM7:TR?= M2nnbnNCVkeHUh?=
NCI-H1355 MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTdwNEW4NFQh|ryP M2HNUHNCVkeHUh?=
RPMI-8226 M4GyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TzR2lEPTB;Nz61NFc{QSEQvF2= MYjTRW5ITVJ?
ARH-77 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTdwNUO1PVch|ryP M{HQ[XNCVkeHUh?=
MN-60 NWjlZoRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTNbVVlUUN3ME23MlU1ODh6IN88US=> MXPTRW5ITVJ?
IMR-5 NIXuSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXpTWM2OD15MEW0PFc3KM7:TR?= MmrFV2FPT0WU
KARPAS-422 NXT2fmdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\5UWlEPTB;Nz61O|IxPiEQvF2= MmLWV2FPT0WU
CA46 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnUTWM2OD15LkW4NFEzKM7:TR?= M3r0[XNCVkeHUh?=
SJSA-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL0UYNXUUN3ME23MlY3ODZzIN88US=> MlTVV2FPT0WU
no-11 M4LwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTdwN{e1OVch|ryP MmjjV2FPT0WU
IST-SL1 M2Dw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TnRWlEPTB;OD6wNlQyPyEQvF2= MlrGV2FPT0WU
NCI-H209 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\oTWM2OD16LkGxOlUzKM7:TR?= NEjl[ZVUSU6JRWK=
TALL-1 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonlTWM2OD16LkG4N|g1KM7:TR?= NXXIVIo1W0GQR1XS
KMOE-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjCTWM2OD16LkG5OFIh|ryP MlTqV2FPT0WU
HCC1599 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPQZ2ZDUUN3ME24MlE6QTh5IN88US=> M4LvZnNCVkeHUh?=
CI-1 NEC0[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nEXWlEPTB;OD6yNFQyOSEQvF2= M4rCdXNCVkeHUh?=
NCI-H1304 MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRThwMkC2OlEh|ryP NFP5eotUSU6JRWK=
Daudi MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XF[mlEPTB;OD6yN|U1PiEQvF2= NV\tOGk6W0GQR1XS
CPC-N M4DOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRThwMkmxPVkh|ryP NVnBd443W0GQR1XS
MC-CAR MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG2NWFKSzVyPUiuN|M2QCEQvF2= MXXTRW5ITVJ?
SW872 NYfMVm9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\2[HFKSzVyPUiuN|Q4PThizszN MnfQV2FPT0WU
OVCAR-4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRThwNUCzOVEh|ryP MofEV2FPT0WU
OCUB-M NH7yS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRThwNU[1NFgh|ryP M{HzeHNCVkeHUh?=
SK-PN-DW M3jYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRThwNkC5PFUh|ryP MWHTRW5ITVJ?
NCCIT NETMXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv2UodKSzVyPUiuO|E4PDVizszN MorjV2FPT0WU
NCI-H1648 MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPvOI9KSzVyPUmuNVM5OzRizszN MnXWV2FPT0WU
COR-L279 MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTlwM{mwPUDPxE1? M{fpbXNCVkeHUh?=
LS-123 NETBXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LWSmlEPTB;OT62PFE3OSEQvF2= M4\QXXNCVkeHUh?=
LP-1 M4DiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLMSHFKSzVyPUmuO|gxQDNizszN Ml7NV2FPT0WU
NB13 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTlwN{m5PVQh|ryP MX7TRW5ITVJ?
ONS-76 MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jPS2lEPTB;OT64NVAyPiEQvF2= MWLTRW5ITVJ?
VA-ES-BJ MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u3[GlEPTB;OT65PVk{OyEQvF2= MYXTRW5ITVJ?
GR-ST NWPrXo8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETlfHNKSzVyPUGwMlIzODdizszN NGL1fIlUSU6JRWK=
ES1 M{m2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknwTWM2OD1zMD6yPVg1KM7:TR?= MYLTRW5ITVJ?
NB14 M4iyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XJcGlEPTB;MUCuPVI4PyEQvF2= MmPxV2FPT0WU
Ramos-2G6-4C10 MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnCTWM2OD1zMT6yOlUh|ryP MljZV2FPT0WU
RXF393 NIfCTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTFzLkS4N|Qh|ryP M{T1dnNCVkeHUh?=
NCI-H2107 NG\QXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ZTWM2OD1zMT61PVg1KM7:TR?= NX:wN4pFW0GQR1XS
K562 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPsSlN1UUN3ME2xNU45PzB{IN88US=> MnfJV2FPT0WU
LOUCY MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofiTWM2OD1zMT65PFc2KM7:TR?= NXXlfHRTW0GQR1XS
TGBC1TKB NXL0bmlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIKxdnBKSzVyPUGyMlAxOiEQvF2= NUPYUmJIW0GQR1XS
COLO-320-HSR NX3qS29FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjz[3pKSzVyPUGyMlE2PjVizszN NYm0NIJ4W0GQR1XS
K5 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W5dWlEPTB;MUKuNlk5PSEQvF2= NFXpcIVUSU6JRWK=
BC-3 NWjjb2M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS1TWM2OD1zMj60OlUyKM7:TR?= Ml3JV2FPT0WU
REH M1zH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HBPGlEPTB;MUKuOlQ6QCEQvF2= MXzTRW5ITVJ?
NEC8 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LsOmlEPTB;MUKuOlg5PyEQvF2= NG\NWG1USU6JRWK=
IST-MEL1 M1\oU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvSWXJMUUN3ME2xNk45Pjl2IN88US=> Mly1V2FPT0WU
NCI-H128 NUPFOZF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:4SGlEPTB;MUOuNFczOyEQvF2= MnXPV2FPT0WU
NCI-H1694 NUGwW3c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjROIx1UUN3ME2xN{4yOTR2IN88US=> NVrQW2NmW0GQR1XS
TGW NGjBfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW4[GlKSzVyPUGzMlMzPzZizszN Ml7VV2FPT0WU
NCI-SNU-1 M{L1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGwTWM2OD1zMz6zOFUh|ryP NEe1d2hUSU6JRWK=
IST-MES1 NIH6cIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7IT|RKSzVyPUGzMlY4OjlizszN MnfYV2FPT0WU
CTB-1 NInVZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;Z[oU3UUN3ME2xN{44Ojl2IN88US=> MW\TRW5ITVJ?
HUTU-80 NYjGXHZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PX[GlEPTB;MUOuO|U4OyEQvF2= NVvGcG9oW0GQR1XS
LAN-6 NF\rVnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;RTWM2OD1zND6yOFU4KM7:TR?= MlS5V2FPT0WU
KP-N-YS MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPZUngyUUN3ME2xOE4zQDl2IN88US=> NEXGTpBUSU6JRWK=
CCRF-CEM MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF2LkSxOlkh|ryP MoPyV2FPT0WU
NCI-H1770 NFS1UW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjFTIVKSzVyPUG0MlU{PjlizszN NVvPWlhJW0GQR1XS
MZ2-MEL M3PpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW5TWM2OD1zNT6yNlUyKM7:TR?= NHf3[GdUSU6JRWK=
COR-L88 MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;sTXNKSzVyPUG2MlAxOTJizszN NYi4Uo95W0GQR1XS
LOXIMVI NWC4SHB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG0ZmtKSzVyPUG2MlI2PiEQvF2= MkPPV2FPT0WU
KALS-1 NFTYUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS2UmhpUUN3ME2xOk42QTNzIN88US=> NIrRdGJUSU6JRWK=
D-283MED MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\UUG1XUUN3ME2xOk45PDh7IN88US=> NV7mNmZmW0GQR1XS
NCI-H719 M37Xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF4LkmxOlEh|ryP MW\TRW5ITVJ?
MLMA Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rIdWlEPTB;MU[uPVkxPyEQvF2= NFX4RZFUSU6JRWK=
EVSA-T MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfMeGVrUUN3ME2xO{4xPDh3IN88US=> Mm\XV2FPT0WU
SK-N-FI NG\p[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW1Ro1KSzVyPUG3MlY6OTNizszN MX;TRW5ITVJ?
NTERA-S-cl-D1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rT[mlEPTB;MUeuPFU4OiEQvF2= NIjCeVBUSU6JRWK=
NCI-H1882 NXPJ[3lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF5Lkm4N|Qh|ryP M1PJ[3NCVkeHUh?=
A704 NGLieXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jnWWlEPTB;MUeuPVkxPCEQvF2= MVTTRW5ITVJ?
L-428 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzNTWM2OD1zOD6wNVUyKM7:TR?= M{GxUHNCVkeHUh?=
HCC1187 NYTOOJYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn0S5RKSzVyPUG4MlAyQDdizszN MWXTRW5ITVJ?
NCI-H1581 NH6yRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\GUmlEPTB;MUiuNFg3PiEQvF2= M4f4V3NCVkeHUh?=
BB65-RCC M{T0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK5TWM2OD1zOD60NVYzKM7:TR?= M1PDb3NCVkeHUh?=
EM-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTHU5ZKSzVyPUG4MlU3PzJizszN NYr0bGFIW0GQR1XS
Raji MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLLPXFKSzVyPUG5Mlk2PjVizszN NYTZbIl4W0GQR1XS
TE-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfSW5ZKSzVyPUKwMlQyODRizszN NHnwZlhUSU6JRWK=
SW962 M2flemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTpNI1KSzVyPUKwMlQzQTNizszN M1rqNHNCVkeHUh?=
MHH-NB-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3FTWM2OD1{MD61OVIyKM7:TR?= MmnsV2FPT0WU
no-10 NX3vS29CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO4TWM2OD1{MT6wNlY1KM7:TR?= NUK2b3h5W0GQR1XS
GDM-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HZO2lEPTB;MkGuPVQyPCEQvF2= MYnTRW5ITVJ?
KMS-12-PE MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TnVGlEPTB;MkKuNlc1KM7:TR?= M1\IVHNCVkeHUh?=
NCI-H510A NELVN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH2T2tbUUN3ME2yOE4yOjd6IN88US=> NWLWRVJjW0GQR1XS
ES5 NW\WRY86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H0dGlEPTB;MkSuO|M1QSEQvF2= NI[4Z|JUSU6JRWK=
JiyoyeP-2003 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvTXIxpUUN3ME2yOk4zPzR{IN88US=> MYLTRW5ITVJ?
NMC-G1 NF;kNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HjNmlEPTB;MkeuNVgzOiEQvF2= MYHTRW5ITVJ?
NCI-H446 NWn3W|VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXtXINKUUN3ME2yO{41QTR4IN88US=> NF;5SG5USU6JRWK=
NB7 MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ5LkmyNlkh|ryP MWXTRW5ITVJ?
A388 M{PwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\md3pKSzVyPUK4MlAxPzRizszN MUDTRW5ITVJ?
JVM-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDKbVdKSzVyPUK4MlI5QThizszN NVfxR5d2W0GQR1XS
HT-144 NIHTZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJ6Lk[5JO69VQ>? M1niSHNCVkeHUh?=
NCI-H747 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXxRmpKSzVyPUK4MlkyQTVizszN NUXXe3ZzW0GQR1XS
NCI-H1650 M1ziT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ7LkCxO|Yh|ryP NHe0NHFUSU6JRWK=
EB-3 Ml7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\tTWM2OD1{OT61N|A6KM7:TR?= MUXTRW5ITVJ?
KLE NF63[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfNTWM2OD1{OT62NVkh|ryP M3niTnNCVkeHUh?=
TK10 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTNyLkGyOkDPxE1? NUfYZWViW0GQR1XS
COLO-668 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTNyLke5NkDPxE1? NVLGW3RvW0GQR1XS
NCI-H23 NEXlcmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXewVnNQUUN3ME2zNU4yODZ|IN88US=> MmW0V2FPT0WU
GOTO M4q4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:2RmZzUUN3ME2zNU43ODh3IN88US=> M3vTWnNCVkeHUh?=
MSTO-211H MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXaWFlKSzVyPUOxMlg3PzhizszN NVHROXdVW0GQR1XS
LB831-BLC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TLRmlEPTB;M{KuN|g1OyEQvF2= NUnMfnNFW0GQR1XS
SCH NGnIdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN{Lki0PFUh|ryP NGTIb5BUSU6JRWK=
EHEB MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH1TWM2OD1|ND6xNVk{KM7:TR?= MVjTRW5ITVJ?
U-266 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjrS4RKSzVyPUO0MlI4QDFizszN MmL6V2FPT0WU
EW-11 MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO0RnpZUUN3ME2zOE41PzJ3IN88US=> NGrwXJRUSU6JRWK=
TE-9 M1HZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;BbXNKSzVyPUO3MlA1ODFizszN NYL5SnFJW0GQR1XS
ES3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfaTWM2OD1|Nz61NFA1KM7:TR?= M1r5VXNCVkeHUh?=
NCI-H2141 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\KZWlEPTB;M{iuNFg1OyEQvF2= MUTTRW5ITVJ?
MPP-89 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TwZmlEPTB;NEKuNFU5PiEQvF2= MYPTRW5ITVJ?
SK-MEL-2 M4XaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm3Oo5uUUN3ME20Nk43PDB3IN88US=> MoHRV2FPT0WU
LC-1F NEnVXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn1cXBkUUN3ME20N{4{Pjh{IN88US=> NHj0V3hUSU6JRWK=
NH-12 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTR|LkmzOVkh|ryP NFfJNZdUSU6JRWK=
RKO MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknCTWM2OD12ND6xNlUzKM7:TR?= MXvTRW5ITVJ?
KM-H2 NX3kZ3BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17kUGlEPTB;NESuPVU4PyEQvF2= NHO5W4NUSU6JRWK=
SK-UT-1 M2jO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTR7Lki4NlUh|ryP M2rIfHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
+ Expand
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03463460 Suspended Thymic Carcinoma Dwight Owen|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center June 19 2018 Phase 2
NCT03463460 Suspended Thymic Carcinoma Dwight Owen|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center June 19 2018 Phase 2
NCT02761057 Recruiting Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma National Cancer Institute (NCI)|Canadian Cancer Trials Group April 5 2016 Phase 2
NCT02761057 Recruiting Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma National Cancer Institute (NCI)|Canadian Cancer Trials Group April 5 2016 Phase 2
NCT02779283 Recruiting Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia OHSU Knight Cancer Institute|National Cancer Institute (NCI) January 13 2016 Phase 1
NCT02779283 Recruiting Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia OHSU Knight Cancer Institute|National Cancer Institute (NCI) January 13 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products4

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID